{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:19:50Z","timestamp":1764937190236,"version":"3.41.2"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00293","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T05:54:02Z","timestamp":1593496442000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Diverse Clinical Presentations of C3 Dominant Glomerulonephritis"],"prefix":"10.3389","volume":"7","author":[{"given":"Ramy M.","family":"Hanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huma","family":"Hasnain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Arman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Selamet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Olanrewaju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Barsoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Yabu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/ki.2013.340","article-title":"Toward a working definition of C3 glomerulopathy by immunofluorescence","volume":"85","author":"Hou","year":"2014","journal-title":"Kidney Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","article-title":"The role of complement in C3 glomerulopathy","volume":"67","author":"Zipfel","year":"2015","journal-title":"Mol Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1681\/ASN.2007030356","article-title":"New approaches to the treatment of dense deposit disease","volume":"18","author":"Smith","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1093\/ndt\/gfr422","article-title":"Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis","volume":"26","author":"Brackman","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/ndt\/gfu317","article-title":"Update on C3 glomerulopathy","volume":"31","author":"Barbour","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"B7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fped.2016.00045","article-title":"Overview of C3 Glomerulopathy","volume":"4","author":"Master Sankar Raj","year":"2016","journal-title":"Front Pediatr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B10","first-page":"240","article-title":"Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis","volume":"18","author":"Schena","year":"1982","journal-title":"Clin Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/j.ajkd.2017.07.004","article-title":"C4 Nephritic factors in C3 glomerulopathy: a case series","volume":"70","author":"Zhang","year":"2017","journal-title":"Am J Kidney Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.molimm.2010.02.002","article-title":"Anti-factor B autoantibody in dense deposit disease","volume":"47","author":"Strobel","year":"2010","journal-title":"Mol Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1055\/s-0034-1376334","article-title":"C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis","volume":"40","author":"Xiao","year":"2014","journal-title":"Semin Thromb Hemost."},{"key":"B15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.nefro.2016.01.014","article-title":"Autoantibodies against alternative complement pathway proteins in renal pathologies","volume":"36","author":"Nozal","year":"2016","journal-title":"Nefrologia."},{"key":"B16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.5527\/wjn.v5.i4.308","article-title":"Reclassification of membranoproliferative glomerulonephritis: identification of a new GN: C3GN","volume":"5","author":"Salvadori","year":"2016","journal-title":"World J Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"695131","DOI":"10.1155\/2012\/695131","article-title":"Kidney diseases caused by complement dysregulation: acquired, inherited, and still more to come","volume":"2012","author":"Heeringa","year":"2012","journal-title":"Clin Dev Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3389\/fimmu.2019.01308","article-title":"Complement nomenclature-deconvoluted","volume":"10","author":"Bohlson","year":"2019","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3389\/fimmu.2019.00886","article-title":"Nephritic factors: an overview of classification, diagnostic tools and clinical associations","volume":"10","author":"Corvillo","year":"2019","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4103\/0971-4065.134089","article-title":"Current concepts in C3 glomerulopathy","volume":"24","author":"Thomas","year":"2014","journal-title":"Indian J Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1681\/ASN.2015040348","article-title":"A Familial C3GN secondary to defective C3 regulation by complement receptor 1 and complement factor H","volume":"27","author":"Chauvet","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00467-015-3307-z","article-title":"Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis","volume":"31","author":"Kawasaki","year":"2016","journal-title":"Pediatr Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2215\/CJN.08520814","article-title":"Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome","volume":"10","author":"Mele","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"B25","unstructured":"SmithR\n          Molecular Otolaryngology and Renal Research Laboratories2020"},{"key":"B26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: is it really effective?","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1186\/1756-0500-7-792","article-title":"Successful management of a patient with a C3 Glomerulonephritis and crescentic pattern: a case report","volume":"7","author":"Pinho","year":"2014","journal-title":"BMC Res Notes."},{"key":"B28","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1053\/j.ajkd.2015.02.326","article-title":"Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome","volume":"65","author":"Bu","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3389\/fimmu.2019.01282","article-title":"Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database","volume":"10","author":"Puraswani","year":"2019","journal-title":"Front Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.4049\/jimmunol.1402770","article-title":"Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases","volume":"194","author":"Blanc","year":"2015","journal-title":"J Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 glomerulopathy: a new classification","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jmg.2006.045328","article-title":"Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome","volume":"44","author":"Servais","year":"2007","journal-title":"J Med Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00467-017-3702-8","article-title":"C3 glomerulonephritis with a severe crescentic phenotype","volume":"32","author":"Ravindran","year":"2017","journal-title":"Pediatr Nephrol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ekir.2018.01.005","article-title":"Renal and pulmonary dense deposit disease presenting as pulmonary-renal syndrome","volume":"3","author":"Nada","year":"2018","journal-title":"Kidney Int Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ki.2015.195","article-title":"Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits","volume":"88","author":"Larsen","year":"2015","journal-title":"Kidney Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000445127","article-title":"Comprehensive analysis of complement genes in patients with atypical hemolytic uremic syndrome","volume":"43","author":"Zhang","year":"2016","journal-title":"Am J Nephrol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1053\/j.ajkd.2018.09.002","article-title":"Kidney transplantation in C3 glomerulopathy: a case series","volume":"73","author":"Regunathan-Shenk","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2180508","DOI":"10.1155\/2017\/2180508","article-title":"Rituximab for treatment of membranoproliferative glomerulonephritis and C3 glomerulopathies","volume":"2017","author":"Rudnicki","year":"2017","journal-title":"Biomed Res Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000479014","article-title":"Immunosuppressive treatment in C3 glomerulopathy: time to reconsider our approach","volume":"46","author":"Tesar","year":"2017","journal-title":"Am J Nephrol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12882-017-0802-4","article-title":"Treating C3 glomerulopathy with eculizumab","volume":"19","author":"Welte","year":"2018","journal-title":"BMC Nephrol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1093\/ndt\/gfx369","article-title":"C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab","volume":"33","author":"Garg","year":"2018","journal-title":"Nephrol Dial Transplant."},{"key":"B45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000492033","article-title":"When to stop eculizumab in complement-mediated thrombotic microangiopathies","volume":"48","author":"Olson","year":"2018","journal-title":"Am J Nephrol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e4843","DOI":"10.1097\/MD.0000000000004843","article-title":"C3 glomerulonephritis in multiple myeloma: a case report and literature review","volume":"95","author":"Yin","year":"2016","journal-title":"Medicine (Baltimore)."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00293\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T05:54:05Z","timestamp":1593496445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00293\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":47,"alternative-id":["10.3389\/fmed.2020.00293"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00293","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"article-number":"293"}}